Allworth Financial LP Sells 160 Shares of Hologic, Inc. (NASDAQ:HOLX)

Allworth Financial LP cut its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 565 shares of the medical equipment provider’s stock after selling 160 shares during the quarter. Allworth Financial LP’s holdings in Hologic were worth $46,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wolff Wiese Magana LLC purchased a new position in Hologic in the third quarter valued at about $25,000. Innealta Capital LLC purchased a new position in Hologic in the second quarter valued at about $25,000. iA Global Asset Management Inc. purchased a new position in Hologic in the first quarter valued at about $37,000. Sunbelt Securities Inc. purchased a new position in Hologic in the second quarter valued at about $37,000. Finally, Cromwell Holdings LLC boosted its stake in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 416 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HOLX has been the topic of a number of research analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Stephens reissued an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research report on Tuesday, October 15th. Leerink Partners lowered their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Evercore ISI boosted their price target on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $87.50.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $82.33 on Friday. The company’s fifty day moving average price is $80.99 and its 200-day moving average price is $77.98. The firm has a market capitalization of $19.12 billion, a price-to-earnings ratio of 28.00, a PEG ratio of 2.94 and a beta of 0.98. Hologic, Inc. has a one year low of $66.53 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32.

Insider Transactions at Hologic

In other news, insider Brandon Schnittker sold 476 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.